FDA approves Novartis brain tumour drug

Oct 30, 2010

Swiss pharmaceutical company Novartis said Saturday that the US drug Food and Drug Administration had approved a drug for treating certain benign brain tumours which previously required surgery.

Everolimus, marketed as Afinitor, had been shown to be effective in reducing subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis, a affecting approximately 25,000 to 40,000 people, mainly children and , in the United States, it said.

Accelerated FDA approval was based on a study of 28 patients conducted by Cincinnati Children's Hospital Medical Center, in which nearly one-third of experienced a reduction of 50 percent or more in the size of their largest SEGA within six months, Novartis said.

The company said it was continuing to study the efficacy and clinical benefit of Afinitor in a wider trial, and had submitted marketing applications to the European Medicines Agency and the Swiss Agency for Therapeutic Products (Swissmedic).

If approved in the European Union for this indication, the treatment will be made available under the trade name Votubia, it said.

Explore further: Benzodiazepine sedatives linked to higher rates of mortality compared to propofol

add to favorites email to friend print save as pdf

Related Stories

Novartis denies problems with swine flu vaccine

Oct 26, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

Novartis gains FDA approval for new MS drug

Sep 22, 2010

(AP) -- Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

Recommended for you

Merck completes sale of consumer unit to Bayer

5 hours ago

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments : 0